136 related articles for article (PubMed ID: 27932144)
1. Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.
Martina MN; Ramirez Bajo MJ; Bañon-Maneus E; Moya Rull D; Hierro-Garcia N; Revuelta I; Campistol JM; Rovira J; Diekmann F
Transplant Proc; 2016 Nov; 48(9):3046-3052. PubMed ID: 27932144
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro.
Wang SP; Iwata S; Nakayamada S; Sakata K; Yamaoka K; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2213-5. PubMed ID: 25157177
[No Abstract] [Full Text] [Related]
3. Fate of lymphocytes after withdrawal of tofacitinib treatment.
Piscianz E; Valencic E; Cuzzoni E; De Iudicibus S; De Lorenzo E; Decorti G; Tommasini A
PLoS One; 2014; 9(1):e85463. PubMed ID: 24416411
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
Rovira J; Ramírez-Bajo MJ; Banon-Maneus E; Lazo-Rodríguez M; Moya-Rull D; Hierro-Garcia N; Tubita V; Piñeiro GJ; Revuelta I; Ventura-Aguiar P; Cucchiari D; Oppenheimer F; Brunet M; Campistol JM; Diekmann F
Transplantation; 2018 Jul; 102(7):1075-1084. PubMed ID: 29620612
[TBL] [Abstract][Full Text] [Related]
5. Impact of tofacitinib treatment on human B-cells in vitro and in vivo.
Rizzi M; Lorenzetti R; Fischer K; Staniek J; Janowska I; Troilo A; Strohmeier V; Erlacher M; Kunze M; Bannert B; Kyburz D; Voll RE; Venhoff N; Thiel J
J Autoimmun; 2017 Feb; 77():55-66. PubMed ID: 27793425
[TBL] [Abstract][Full Text] [Related]
6. Combined standard and novel immunosuppressive substances affect B-lymphocyte function.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Int Immunopharmacol; 2013 Apr; 15(4):718-25. PubMed ID: 23499640
[TBL] [Abstract][Full Text] [Related]
7. Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Unterwalder N; Doueiri S; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Transpl Int; 2012 Oct; 25(10):1106-16. PubMed ID: 22816666
[TBL] [Abstract][Full Text] [Related]
8. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
10. Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses.
Kovarik JM; Stitah S; Slade A; Vitaliti A; Straube F; Grenet O; Winter S; Sfikas N; Seiberling M
J Clin Pharmacol; 2010 Nov; 50(11):1260-6. PubMed ID: 20386017
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib.
Adis Editorial
Drugs R D; 2010; 10(4):271-84. PubMed ID: 21171673
[TBL] [Abstract][Full Text] [Related]
12. Overview of sotrastaurin clinical pharmacokinetics.
Kovarik JM; Slade A
Ther Drug Monit; 2010 Oct; 32(5):540-3. PubMed ID: 20683390
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
14. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.
van Gurp EA; Schoordijk-Verschoor W; Klepper M; Korevaar SS; Chan G; Weimar W; Baan CC
Transplantation; 2009 Jan; 87(1):79-86. PubMed ID: 19136895
[TBL] [Abstract][Full Text] [Related]
15. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.
Evenou JP; Wagner J; Zenke G; Brinkmann V; Wagner K; Kovarik J; Welzenbach KA; Weitz-Schmidt G; Guntermann C; Towbin H; Cottens S; Kaminski S; Letschka T; Lutz-Nicoladoni C; Gruber T; Hermann-Kleiter N; Thuille N; Baier G
J Pharmacol Exp Ther; 2009 Sep; 330(3):792-801. PubMed ID: 19491325
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib in kidney transplantation.
Wojciechowski D; Vincenti F
Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effect and mechanism of tofacitinib on the secretion of cytokines by T cells in human peripheral blood].
Wu K; Zhao J; Wu Q; Wu C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Nov; 33(11):1448-1455. PubMed ID: 29268845
[TBL] [Abstract][Full Text] [Related]
18. Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes.
Piscianz E; Candilera V; Valencic E; Loganes C; Paron G; De Iudicibus S; Decorti G; Tommasini A
Mol Med Rep; 2016 Jul; 14(1):574-82. PubMed ID: 27175898
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
20. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin.
Heidt S; Roelen DL; Eijsink C; van Kooten C; Claas FH; Mulder A
Transplantation; 2008 Nov; 86(9):1292-300. PubMed ID: 19005412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
